scholarly journals Early Cytokine Removal in Critical COVID-19 Patients with Extracorporeal Therapies (HA-380 plus High Volume Hemofiltration) May Prevent Progression of Acute Respiratory Distress Syndrome: Case Report

2020 ◽  
pp. 1-3
Author(s):  
Gonzalo Ramírez-Guerrero ◽  
Vicente Torres Cifuentes ◽  
Romyna Baghetti Hernández ◽  
Francisco Villagrán Cortés ◽  
Simón Rojas Doll ◽  
...  
Keyword(s):  
Acute Respiratory Distress Syndrome ◽  
Respiratory Distress Syndrome ◽  
Respiratory Distress ◽  
Clinical Case ◽  
Distress Syndrome ◽  
High Volume ◽  
Cytokine Release ◽  
Cytokine Release Syndrome ◽  
Hemodynamic Deterioration ◽  
High Volume Hemofiltration

We present the case of a patient who suffered from acute respiratory distress syndrome caused by pneumonia associated with COVID-19 and cytokine release syndrome. This patient received a high-volume hemofiltration plus adsorption, solving the hemodynamic deterioration, pulmonary infiltrates, and gas exchange. Our clinical case proposes that the extracorporeal therapies can have a role in the management of severe COVID-19.

scholarly journals Combined effects of Tocilizumab and Remdesivir in severe COVID- 19 patient with cytokine release syndrome: A case-report (Preprint)

2021 ◽  
Author(s):  
Sabahat Ali ◽  
Sundas Khalid ◽  
Maham Afridi ◽  
Samar Akhtar ◽  
Yousef S. Khader ◽  
...  
Keyword(s):  
Acute Respiratory Distress Syndrome ◽  
Severe Acute Respiratory Syndrome ◽  
Respiratory Distress Syndrome ◽  
Respiratory Distress ◽  
Distress Syndrome ◽  
Virus Disease ◽  
Cytokine Release ◽  
Cytokine Release Syndrome ◽  
Treatment Regimens ◽  
Corona Virus

BACKGROUND Novel corona virus (nCoV) or Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is known to cause severe bilateral pneumonia and acute respiratory distress syndrome (ARDS) or Corona virus disease-2019 (COVID-19) in patients that can be debilitating and even fatal. With no drugs or vaccines available yet, a wide range of treatment regimens used are being repurposed. The need of the hour is to analyze various regimens available and devise a treatment plan most effective against SARS-CoV-2. OBJECTIVE Patient concerns: A 68-year-old hypertensive, diabetic male, exhibiting symptoms of cough and shortness of breath presented at the emergency department of our hospital. Diagnosis: Chest CT revealed bilateral ground glass opacities indicative of COVID-19 and the CT score of 24 indicated severe pulmonary pneumonia. He tested positive for COVID-19. METHODS Interventions: The treatment regimen included use of convalescent plasma, oxygen therapy, steroids, high dose antibiotics, broad spectrum antiviral Remdesivir, and anti-interleukin-6 monoclonal antibody/Tocilizumab at various stages of the disease. RESULTS Outcomes: Oxygen support was required at the time of admission. The patient initially developed cytokine release storm and mechanical ventilation was used to manage his condition. Supportive care and multiple treatment regimens were used to successfully recover the patient’s health. CONCLUSIONS Lessons: With a rapid increase in number of confirmed cases worldwide, COVID-19 has become a major challenge to our healthcare system. With no available vaccines currently, finding a combination of therapeutic drugs which are effective in reducing progression of disease is of utmost importance. CLINICALTRIAL Abbreviations:COVID-19=Corona virus disease 2019, nCoV=Novel corona virus (nCoV), SARS-CoV-2=Severe acute respiratory syndrome coronavirus 2, ARDS=acute respiratory distress syndrome, RT PCR= real-time polymerase chain reaction, SPO2= oxygen saturation, ICU=Intensive Care Unit, GGO=ground glass opacities, TDS=thrice daily, OD=once daily, BD= twice daily, CRS= cytokine release syndrome, CPAP=continuous positive airway pressure,FiO2= fraction of inspired oxygen, PEEP=positive end-expiratory pressure, PSV= pressure support ventilation.

Neuromuscular Blockers in Early Acute Respiratory Distress Syndrome

2018 ◽  
pp. 123-128
Author(s):  
Duncan McLean ◽  
Matthias Eikermann
Keyword(s):  
Acute Respiratory Distress Syndrome ◽  
Respiratory Distress Syndrome ◽  
Respiratory Distress ◽  
Clinical Case ◽  
Distress Syndrome ◽  
Neuromuscular Blocking ◽  
Neuromuscular Blocking Agents ◽  
Neuromuscular Blockers ◽  
Study Intervention

This chapter provides a summary of the landmark study known as Neuromuscular Blockers in Early Acute Respiratory Distress Syndrome. Do neuromuscular blocking agents (NMBs) improve outcomes in patients with acute respiratory distress syndrome who are receiving mechanical ventilation? Starting with that question, the chapter describes the basics of the study, including funding, study location, who was studied, how many patients, study design, study intervention, follow-up, endpoints, results, and criticism, and limitations. The chapter briefly reviews other relevant studies and information, discusses implications, and concludes with a relevant clinical case. The study found that patients with severe ARDS may benefit from short-term NMB infusions with certain caveats, as noted in the chapter.

Sign in / Sign up

Export Citation Format

Share Document